Sibutramine

Drug #1591

Sibutramine is an antiobesity drug, Sibutramine is structurally related to amphetamine. Sibutramine is a serotonin and noradrenaline reuptake inhibitor. It should be avoided in anorexia nervosa or in poorly controlled or uncontrolled hypertension.

← Previous drug Next drug →

Primary Characteristics

Sibutramine is also known as Sibutramine HCl.

It is of Synthetic origin.

Molecular Weight: 279.8 · Non-proprietary name: Sibutramine.

Pharmacokinetics

Distribution: Sibutramine has a plasma protein binding is 97%.

Elimination: it is metabolised via Hepatic, plasma half-life is 14-16 hr, renal excretion is 0%.

Indications

Sibutramine is primarily indicated in conditions like Bleeding caused by uterine atony, Obesity.

Contraindications

Sibutramine is contraindicated in conditions like Hyperthyroidism, Phaeochromocytoma, Prostatic hypertrophy, Congestive heart failure, Cerebrovascular disease, Angle-closure glaucoma, Coronary artery disease, Uncontrolled hypertension, Peripheral arterial occlusive disease, Psychotic illness, Thyrotoxicosis (adjunct), Infections due to senstive gram +ve and gram -ve bacteria.

Dosage

Sibutramine's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
10 mg	10 mg	Every 24h	PO	Initially, increased to 15mg if weight loss is <2 kg after 4 weeks. Max. period of treatment 1yr.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

Unknown11 interactions

1 interaction

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Sibutramine in overdosage may give rise to further complications which include Increased blood pressure , Seizures , Bleeding , Acute interstitial nephritis , Migraine .

Sibutramine is known to cause more or less tolerable side effects which are usually transient. These include Constipation , Depression, Diarrhea, Dizziness, Dry mouth, Dysmenorrhea, Edema, Headache, Insomnia, Rhinitis .

Warnings / Precautions

Monitor blood pressure and pulse rate (every two weeks for first three months then monthly for three months then atleast every three months)---- discontinue if blood pressure exeeds 145/90 mmHg or if systolic or diastolic pressure raised by 10mmHg or if pulse rate raised by 10 beats per minute at two consecutive visits; sleep apnoea syndrome (increased risk of hypertension); epilepsy; hepatic impairment (avoid if severe); renal impairment (avoid if severe); monitor for pulmonary hypertension; family history of motor or vocal tics. DISCONTINUATION OF TREATMENT: Discontinue treatment if : weight loss after three months less than 5% of initial body weight; weight loss stabilises at less than 5% of initial body weight; individuals regain 3 kg or more after previous weight loss. In individuals with co-morbid conditions, treatment should be continued only if weight loss is associated with other clinical benefits.

Interference in Pathology

Sibutramine may interfere in the diagnosis of Abnormal LFTs , Increased Alkaline Phosphatase Levels, Elevation in ALT or AST.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Caps

10 mg 15 mg 20 mg

Storage Conditions

Sibutramine should be stored Caps.

Drug Classification

1.17.10 — Antiobesity preparations

Manufacturers

Manufacturers of Sibutramine in Pakistan:

Genix Medicaids Medisure Rakaposhi Tagma